Roth Lab - Research

Roth Lab Research


We have longstanding and ongoing efforts to determine the structural basis for GPCR pharmacology and signaling (Fenalti, Giguere et al, Nature 2014; Wacker et al, Science 2013; Wacker et al, Cell 2017; Wang et al, Science 2017 ).

Systems Pharmacology:

The Roth lab pioneered the approach of massively-parallel physical screening of the entire druggable GPCR-ome (Kroeze et al, Nature Structure and Molecular Biology 2015). Shown is the current coverage of the druggable GPCR-ome using our newest resource (Kroeze et al, 2015; Huang et al, Nature 2015; Lansu et al, Nature Chemical Biology 2017; Resource available from ADDGENE).

Ongoing projects are focused on using this technology to reveal the structure and function of the nearly 200 orphan and sparsely annotated druggable GPCRs NIH Illuminating the Druggable Genome


The Roth lab perfected the chemogenetic technology we have named “DREADD” (Designer Receptor Exclusively Activated by Designer Drugs; Armbruster et al, 2007). DREADD technology has afforded 100’s of labs world-wide the opportunity to discover how cell-type specific modulation of signaling is translated into behavioral and non-behavioral outcomes (see Urban and Roth, Ann Rev Pharmacol Toxicol 2015 for recent review)

The Roth lab continues to enhance DREADD technology (see Vardy et al, Neuron 2015).

We also have made DREADD technology available to the scientific community:
  • All DREADD-related plasmids are available via ADDGENE
  • High titer viral stocks available from ADDGENE